Company Overview and News

0
TCBK / TriCo Bancshares 8-K (Current Report)

2018-07-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

0
ECA2018-112 - Information Regarding the Merger of FNB Bancorp (FNBG) and TriCo Bancshares (TCBK)

2018-07-03 nasdaqtrader
TriCo Bancshares and FNB Bancorp (FNBG) announced on June 6, 2018 the receipt of regulatory approvals for the merger of FNB Bancorp with and into TriCo Bancshares. The merger is anticipated to become effective on Friday, July 6, 2018. The details are as follows:
TCBK FNBG FBIP

259
Stocks To Watch: Tariffs Don't Take Holidays

2018-06-30 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. As usual, a new quarter and the second half of the trading year will begin with a shortened week due to the Independence Day holiday -- a "trading week interruptus," with July 4 landing on Wednesday.
TCBK FBIP TCYSF SIRI ISCA 1128 MT CUKPF FNBG GM.WS.A GM.WS.B GM.WS.C 1928 CBB.PRB NCMI TRBAB AYI SRRK GSKY TRBNW CCL CUK SHERF PSMT MLHR KNSA QCOM FCAU SJMHF GM.WSB PFE SBGI MT RCH SSNLF TM LSXMA NXPI CLPS ZGNX AYI.WI SJMHY MLCO ISCB CCL GM EVOP DIS HCOM F CSTM CMCSA SCHYF CSTM WYNMF LLY MGTX HMC 0880 CBB ITRM BHVN VC RHUHF SIFY 506186 FGEN GLXYENT BHR SNE SCHYY TRCO WYNMY

1
TCBK / TriCo Bancshares 8-K (Prospectus)

2018-06-07 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares 8-K (Prospectus)

2018-06-07 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares 8-K (Current Report)

2018-06-07 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;F5A Q"<[email protected],@609&8HC_C%-^ 08 2Z!NT- M"F5N9'-T
TCBK

1
TCBK / TriCo Bancshares null

2018-05-31 sec.gov
CORRESP TriCo Bancshares 63 Constitution Drive Chico, CA 95973 April 17, 2018 VIA EDGAR
TCBK

1
TCBK / TriCo Bancshares 8-K (Prospectus)

2018-05-31 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares 8-K (Current Report)

2018-05-31 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

3
TriCo Bancshares and FNB Bancorp Announce Shareholder and FDIC Approval of Merger

2018-05-31 accesswire
CHICO, CA and SOUTH SAN FRANCICO, CA / ACCESSWIRE / May 30, 2018 / TriCo Bancshares (''TriCo'') (NASDAQ: TCBK) and FNB Bancorp (''FNB'') (NASDAQ: FNBG) today announced today that each company has received the requisite shareholder approval for the merger of FNB with and into TriCo (''Merger'') that was announced on December 11, 2017.
FLBD TCBK FNBG FBIP

1
TCBK / TriCo Bancshares 8-K (Current Report)

2018-05-28 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares 8-K (Prospectus)

2018-05-28 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares 8-K (Current Report)

2018-05-25 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

1
TCBK / TriCo Bancshares FORM 8-K (Prospectus)

2018-05-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
TCBK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 896095106